Latvian national focal point

This threat assessment examines the evolving presence and impact of highly potent synthetic opioids, particularly the group of 2-benzylbenzimidazole opioids (the so-called ‘nitazenes’) and carfentanil, in Estonia, Latvia and Lithuania.

This data factsheet presents insights from the European Web Survey on Drugs 2024. It provides an overview of key data from 61 732 individuals aged 18 or older who use drugs and live in one of 24 EU countries or Norway.

This page draws on the latest data available to provide an overview of the current situation and emerging drug issues affecting Europe, with a focus on the year up to the end of 2024.

Harm reduction encompasses interventions, programmes and policies that seek to reduce the health, social and economic harms of drug use to individuals, communities and societies. On this page, you can find the latest analysis of harm reduction interventions in Europe, including key data on o

Opioid users represent the largest group undergoing specialist drug treatment, mainly in the form of opioid agonist treatment.

Drug-induced deaths are those that are directly attributable to the use of drugs. On this page, you can find the latest analysis of drug-induced deaths in Europe, including key data on overdose deaths, the substances implicated and more.